Foundayo (Orforglipron): What to Know About the New GLP-1 Weight-Loss Pill

What Changed Since This Article Was First Published?

The biggest change is simple: orforglipron is no longer an investigational weight-loss pill waiting for an FDA decision. On April 1, 2026, FDA approved it under the brand name Foundayo for adults with obesity, or adults with overweight who have at least one weight-related health condition. It is used together with reduced-calorie eating and increased physical activity.

That means the old question—“Will this pill ever be available?”—has been replaced by much more useful questions: How well does it work? How rough are the side effects? What does a normal dose increase look like? What does it cost? And is a daily pill actually a better fit than a weekly injection?

For many people, those questions matter more than the chemistry.

What Is Foundayo, in Plain English?

Foundayo is a once-daily GLP-1 receptor agonist. Like other GLP-1 medicines, it affects appetite and other metabolic signals that can help people eat less and lose weight.

The unusual part is the format. Orforglipron is a small, non-peptide molecule, which allows it to be made as a conventional tablet. You swallow it once a day, and FDA labeling says it can be taken with or without food. You do not have to plan breakfast around it or avoid water for a specific period.

That may sound like a small convenience until you picture real life. Some people leave the house at 5 a.m. Others work rotating shifts. Some travel constantly. Others simply do not want needles in their refrigerator. For those patients, a normal pill can remove a surprisingly large amount of friction.

It does not automatically make Foundayo more effective or easier on the stomach than an injection. It simply gives patients another way to use GLP-1 treatment.

Orforglipron is now FDA-approved as Foundayo, a once-daily oral GLP-1 medicine for long-term weight management in eligible adults.

How Much Weight Did People Lose?

This is where headlines can become confusing because different analyses can produce slightly different percentages. The clearest patient-facing number comes from the large Phase 3 ATTAIN-1 trial and the FDA-approved labeling.

In ATTAIN-1, 3,127 adults with obesity or overweight and a weight-related condition—but without type 2 diabetes—were followed for 72 weeks. Average weight loss at the highest studied dose was about 11.2%, compared with 2.1% for placebo.

That average hides a wide range of responses. At the highest dose:

• about 55% lost at least 10% of their starting weight;
• about 36% lost at least 15%;
• about 18% lost at least 20%.

Those numbers are meaningful, but they are not a promise. If someone starts at 240 pounds, an 11% average would be roughly 26 pounds. One person may lose much more. Another may lose much less. Trial averages are useful for setting expectations, not predicting your exact result.

What About People With Type 2 Diabetes?

The FDA weight-management studies included a separate 72-week trial involving adults with type 2 diabetes and a BMI of at least 27. At the highest Foundayo dose, average weight loss was about 9.6%, compared with 2.5% for placebo.

That is useful information for people who live with both excess weight and diabetes. There is an important labeling distinction, though: as of September 1, 2026, Foundayo’s FDA approval is for long-term weight management. This page should not describe it as an FDA-approved diabetes treatment simply because diabetes trials have shown improvements in blood sugar.

How Do You Actually Take It?

Foundayo is not a medicine that starts at the full dose on day one. The dose is increased slowly to reduce gastrointestinal side effects.

The FDA-approved schedule starts at 0.8 mg once daily. After at least 30 days, the dose increases to 2.5 mg. After another 30 days, it increases to 5.5 mg. Depending on response and tolerance, a provider may later increase it through 9 mg, 14.5 mg, and a maximum of 17.2 mg, with at least 30 days at each step.

That gradual climb is important. If nausea or vomiting becomes difficult, racing to a higher dose because “more must work better” can make treatment harder to stay on. The goal is not to reach the maximum dose as quickly as possible. The goal is to find a dose that produces useful progress without making everyday life miserable.

The Side Effects People Usually Want to Know About

The most common problems are gastrointestinal. At the highest maintenance dose in the FDA trials, nausea occurred in about 35% of patients, diarrhea in 25%, constipation in 24%, and vomiting in 24%.

Most gastrointestinal effects were mild or moderate, and nausea, vomiting, and diarrhea were more common while doses were being increased. They tended to decrease over time. Still, about 6% of patients at the highest dose stopped treatment because of gastrointestinal side effects.

That is the part worth remembering if you are choosing between “a pill” and “a shot.” A tablet may be easier to take, but your stomach does not care whether the GLP-1 signal came through a needle or a pill bottle.

When side effects become more than an inconvenience

The prescribing information includes warnings for pancreatitis, severe gastrointestinal reactions, kidney injury related to dehydration, gallbladder problems, allergic reactions, and other complications. Foundayo can also increase the risk of low blood sugar when used with insulin or certain diabetes medicines.

Foundayo carries a boxed warning related to thyroid C-cell tumors and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. It is not recommended for people with severe gastroparesis.

Pregnancy is another important issue. Weight loss offers no benefit during pregnancy, and FDA labeling says Foundayo should be discontinued when pregnancy is recognized.

Is a Daily Pill Better Than a Weekly Injection?

For some people, yes—simply because they are more likely to take it consistently.

For others, a weekly injection may actually be easier. One shot every seven days can be simpler than remembering a tablet every morning, afternoon, or evening for years. Some patients dislike needles intensely. Others barely care about them.

There is no universal winner here. The more useful comparison is personal:

• Do you dislike injections enough that it affects adherence?
• Would you reliably remember a daily pill?
• How did you tolerate previous GLP-1 treatment?
• Which medicine is actually covered or affordable?
• Which option fits your medical history?

That is a much more realistic way to choose than simply asking which drug produced the largest trial percentage.

What Does Foundayo Cost Right Now?

Price is now a real-world question rather than a future guess.

As of September 1, 2026, LillyDirect lists self-pay pricing starting at $149 per month for the 0.8 mg starting dose. The listed self-pay price is $199 for 2.5 mg, $299 for 5.5 mg and 9 mg, and $349 for 14.5 mg and 17.2 mg. Lilly currently offers a program that can reduce the 14.5 mg and 17.2 mg doses to $299 when program requirements are met, including timely refills.

Eligible commercially insured patients whose plan covers Foundayo may qualify to pay as little as $25 per month. Lilly also describes a Medicare GLP-1 Bridge program through which some eligible Medicare Part D patients may be able to obtain Foundayo for no more than $50 per month.

Those are program prices, not guarantees. Your actual cost can change with insurance, eligibility, dose, pharmacy route, and program rules.

Can You Switch From Wegovy, Zepbound, or Another GLP-1?

Possibly, but there is no safe one-size-fits-all conversion chart patients should follow on their own.

A provider needs to consider what you are taking now, the last dose, side effects, why you want to switch, how much progress you have made, and whether there is a medical reason to prefer one option. Lilly’s own patient information advises people who want to switch to talk with their doctor about the appropriate transition and starting dose.

The fact that Foundayo begins at 0.8 mg does not mean that everyone switching from another GLP-1 should automatically start or escalate in the same way.

What a Foundayo Conversation at Fountain of Youth Can Look Like

For a regular patient, the useful part of the appointment is not a lecture about molecular structure. It is being able to say, “I tried a shot and hated the nausea,” or “I travel every week and want something easier,” or “My insurance stopped covering what I was taking,” and then work through the options.

At Fountain of Youth SWFL in Fort Myers, medical weight-loss care begins with required laboratory work. The provider reviews those results along with your health history, current medications, previous weight-loss attempts, goals, and treatment concerns. If prescription treatment is appropriate, the plan can be discussed in the context of what you can realistically maintain.

Monthly check-ins are required during active care. Those visits give patients a place to talk about appetite changes, constipation, nausea, weight trends, medication access, and whether the current plan still makes sense. Patients actively losing weight complete repeat labs every six months, while maintenance patients complete them annually.

That kind of follow-up matters with a medication that can look wonderfully simple from the outside. One pill a day sounds easy. Staying on a treatment long enough for it to help is where real life enters the picture.

Questions Patients Are Likely to Ask

Is orforglipron approved now?

Yes. FDA approved orforglipron as Foundayo on April 1, 2026, for long-term weight management in eligible adults with obesity or overweight plus at least one weight-related condition.

Do I have to take Foundayo on an empty stomach?

No. FDA labeling says it can be taken once daily with or without food. The tablet should be swallowed whole and should not be crushed, chewed, or broken.

How much weight can I realistically expect to lose?

In the large 72-week obesity trial, average loss at the highest dose was about 11.2%. Some people lost 15% or 20% or more, while others lost considerably less. Your response cannot be predicted from the average alone.

Does the pill cause nausea?

It can. Nausea was one of the most common side effects and affected about 35% of patients at the highest maintenance dose in the FDA trials. Diarrhea, constipation, vomiting, indigestion, and abdominal discomfort were also common.

Is Foundayo cheaper than injectable GLP-1 medicines?

It can be cheaper for some people under current self-pay or insurance programs, but the answer depends on dose and coverage. LillyDirect currently lists self-pay prices from $149 to $349 per month depending on dose, with additional savings programs for eligible patients.

Is Foundayo approved to treat type 2 diabetes?

As of September 1, 2026, its FDA indication is long-term weight management. Clinical trials in people with type 2 diabetes showed weight and blood-sugar improvements, but this page should not describe Foundayo as FDA-approved specifically for diabetes treatment.

Can I take Foundayo with another GLP-1?

FDA labeling says concomitant use with another GLP-1 receptor agonist is not recommended. Medication changes should be planned with the prescribing provider rather than combined or overlapped independently.

Key Sources

• FDA approval announcement – Confirms the April 1, 2026 approval and the approved weight-management indication.
• Foundayo prescribing information – Current dosing, contraindications, warnings, adverse-event rates, and clinical-trial results.
• ATTAIN-1 obesity trial – Peer-reviewed 72-week Phase 3 results in 3,127 adults.
• LillyDirect Foundayo access information – Current availability, self-pay pricing, coverage support, and patient access information.

The Question Is No Longer “Will This Pill Arrive?”

Foundayo has crossed the line from pipeline story to real prescription option. For people who have avoided GLP-1 treatment because they dislike injections, that is a meaningful change.

The pill still has the same kind of questions every long-term obesity treatment should face: Will you tolerate it? Can you afford it? Can you stay consistent? Does it fit your medical history? And is it actually better for you than the alternatives already available?

Those questions are less exciting than an approval headline. They are much more useful.

Medical review: Reviewed by Dr. Keith Lafferty MD, Fort Myers on September 1, 2026. Fact-checked against government and academic sources; see in-text citations. This page follows our Medical Review & Sourcing Policy.